Close Menu

The Scan

A University of Brighton team is pursuing a genetic test for blood doping methods to increase red blood cell levels.

Strategies for sequencing formalin-fixed, paraffin-embedded 5' RNA ends; tumor phylogeny from single-cell and bulk data; a chromosome-level look at the Atlantic herring genome.

The drug works to improve cognitive function in Alzheimer's patients by altering their gut microbiomes, ScienceInsider reports.

Don't Be So Gloomy

A British scientist says Brexit could actually be good for science in the UK.

The New York Times reports there are nearly 200 investigations into potential theft of intellectual property at biomedical research institutions.

In PNAS this week: gut microbiome-diet relationships in large, East African herbivore species, breast cancer features that boost susceptibility to neoadjuvant chemotherapy, and more.

CNN reports that President Donald Trump is to nominate Stephen Hahn as the next Food and Drug Administration commissioner.

The Associated Press reports that an analysis suggests bison are losing their genetic diversity.

Maybe Someday a Test

Researchers in the UK uncovered auto-antibodies that might be able to be used to uncover breast cancer, the Guardian reports.

In PLOS this week: computational approach, analysis of chronic granulomas, and more.

Not a Dime Again

A former Duke University biologist who was found to have fabricated data in 39 papers has been banned from receiving federal funding.

About Those Chips

The dispute regarding the Wellcome Sanger Institute's use of DNA samples from African individuals could weaken trust between researchers and African populations, Science writes.

Quick Confirmation

The Scientist writes that the announcement of Islamic State's Abu Bakr al-Baghdadi's death suggested that his identity might have been confirmed with rapid DNA testing.

In Science this week: DNA exchange influences diversity among Heliconius butterflies, and more.

The American Association for the Advancement of Science names Sudip Parikh as its next CEO.

Some Shrinking

New Scientist writes that experimental cancer drug from Amgen appears effective at targeting cancers with KRAS mutations.

For a Number Boost

PBS NewsHour reports on initiatives that aim to bolster the representation of minority groups in research.

In Nature this week: residual protein expression uncovered for a third of CRISPR targets, and more.

Pause Button Hit

Novartis has paused a trial of its Zolgensma gene therapy that treats spinal muscular atrophy, the Wall Street Journal reports.

CRISPR It Up

The New York Times reports on CRISPR's potential as an antibiotic.

Gottlieb's VC Focus

Reuters reports that Scott Gottlieb, the former Food and Drug Administration commissioner, plans to focus in part on new antibiotics in his venture capital role.

In Genome Biology this week: effect of structural variants in cancer, comparison of human and primate gut microbiomes, and more.

Soon, Soon

The North Jersey Record looks into genetic testing to guide cancer treatment, particularly fluorouracil.

Bringing It Back

Time magazine discusses Biogen's move to resurrect its Alzheimer's disease drug.

The Guardian reports that birds' eggs may be darker in cooler regions because of how they retain heat.

Pages

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.